Results 51 to 60 of about 214,611 (264)

HER2-Positive Gastroesophageal Cancers Are Associated with a Higher Risk of Brain Metastasis

, 2022
Brain metastasis from gastroesophageal adenocarcinomas (GOCs) is a rare but a devastating diagnosis. Human epidermal growth factor receptor 2 (HER2) is a prognostic and predictive biomarker in GOCs.
A Mukhtiar (22506929), Marie Ranson (19586413), A Naveed (16204115), Lorraine Chantrill (19586761), Ann-Katrin Piper (19584151), TM Becker (17906066), Gary Tincknell (19586755), J Nankervis (9851816), Kara Perrow (19585660), Morteza Aghmesheh (19587223), Daniel Brungs (19585414)   +10 more
core   +1 more source

Oncogenic DMTF1β promotes cancer cell motility by regulating autophagy through ULK1 stabilization

Molecular Oncology, EarlyView.
In the current study, we demonstrate that the oncogene DMTF1β regulates ULK1 stability by reducing its proteasomal degradation in cancer cells. This stabilization enables ULK1 to induce autophagy, which in turn facilitates cancer cell migration. Consequently, reduced DMTF1β levels lead to decreased autophagy and impaired cancer cell migration.
Jun Xu, Nicolas J. Niklaus, Anna M. Schläfli, Igor Tokarchuk, Magali Humbert, Federico La Manna, Bich Vu, David Maul, Ramin Radpour, Marianna Kruithof‐de Julio, Inti Zlobec, Jörn Dengjel, Bruce E. Torbett, Mario P. Tschan   +13 more
wiley   +1 more source

Molecular Cloning of DARPins G3 in pET28b Expression Vector and Optimization of the Expression of This Protein in Escherichia Coli [PDF]

Research in Molecular Medicine, 2022
Background: Human epidermal growth factor receptor 2 (HER2) is over-expressed in breast, ovarian, gastric, and prostate cancers and is used as a tumor marker in the diagnosis of cancer. Monoclonal antibodies have been used as a diagnostic and therapeutic
Nadereh Bakhshandeh, Shaban Ali Khodashenas, Mehryar Zargari, Naghi Shahabi Majd, Zeinab Rezaei Kiasari   +4 more
doaj  

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Invasive Breast Cancer with HER2 ≥4.0 and <6.0: Risk Classification and Molecular Typing by a 21-Gene Expression Assay and MammaPrint Plus BluePrint Testing

Breast Cancer: Targets and Therapy, 2023
Qianming Bai,1– 3,* Hong Lv,1– 3,* Longlong Bao,1– 3,* Yu Yang,1– 3 Xin Zhang,4 Heng Chang,1– 3 Tian Xue,1– 3 Min Ren,1– 3 Xiaoli Zhu,1– 3 Xiaoyan Zhou,1– 3,* Wentao Yang1– 3,* 1Department of Pathology, Fudan University Shanghai ...
Bai Q, Lv H, Bao L, Yang Y, Zhang X, Chang H, Xue T, Ren M, Zhu X, Zhou X, Yang W   +10 more
doaj  

Profiling and potential of Marchantia paleacea Bertol. extract for breast anticancer candidate: GC-MS, LC-MS/MS, and in silico analysis [PDF]

Journal of Pharmacy & Pharmacognosy Research
Context: Breast cancer remains a leading cause of cancer-related mortality among women worldwide. Limitations in existing targeted therapies, including resistance, toxicity, and cost, have renewed interest in plant-derived metabolites as potential breast
Etti S. Siregar, Putri C. Situmorang, Nursahara Pasaribu, Hestia Hairima, Mufida R. Hasibuan   +4 more
doaj   +1 more source

Research Progress of PD-1/PD-L1 Inhibitor Combined with Trastuzumab in HER2-positive Breast Cancer

Zhongliu Fangzhi Yanjiu, 2022
HER2 gene is expressed in 20%-30% of breast cancer patients, and HER2 expression provides a new direction for treatment. However, breast cancer with positive HER2 still has a poor prognosis and is prone to recurrence and metastasis.
CHANG Jinyi, WANG Wei, CAI Haifeng
doaj   +1 more source

HER2-L755S mutation induces hyperactive MAPK and PI3K-mTOR signaling, leading to resistance to HER2 tyrosine kinase inhibitor treatment

, 2019
L755S, a HER2 kinase domain mutation, is the most common HER2 mutation in breast cancer associated with resistance to anti-HER2 trastuzumab treatment.
Qian Xiao (385785), Qiang Yu (5487), Wenyu Wang (800903), Panpan Wang (228835), Jiayao Li (109280), Yi Bao (278186), Jianyuan Goh (6743042)   +6 more
core   +1 more source

HER2-low in gastroesophageal adenocarcinoma: a real-world pathological perspective [PDF]

, 2022
openIntroduction: Trastuzumab in combination with cytotoxic chemotherapy is the first-line therapy of choice in HER2-overexpressing metastatic gastroesophageal cancers.
RIGHETTO, ANNA
core  

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source